Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KUP101
- Development stage
- Phase 1
- Lead developer
- Kupando
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
KUP101 is Kupando's clinical-stage **dual Toll-like receptor 4 and Toll-like receptor 7 agonist** immunotherapy. It is a liposomal product containing two co-encapsulated small-molecule agonists intended to stimulate innate immunity and induce trained innate immunity. KUP101 is being evaluated in a first-in-human Phase 1 study for advanced solid tumors, including advanced skin cancers, and is also being developed preclinically as a host-directed approach for infectious diseases, including antimicrobial-resistant infections.
02
Targets
TLR4 (Toll-like receptor 4)TLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on KUP101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KUP101.